Company intelligence / Profile preview
Planeeria
Lod, Israelplaneeria.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Planeeria was an emerging biotechnology start-up focused on the development of innovative tissue regeneration products for orthopedic applications. Founded in 2018 as a spin-off of Prudentix, the company developed Remelix, a pioneering, sterile, injectable biological therapy based on recombinant human amelogenin (rAmelX) technology. Remelix is designed as a local, single-dose intra-joint injection to treat injured articular cartilage and ligaments in traumatized joints by recruiting mesenchymal stem cells and pericytes to promote natural healing. Although Planeeria ceased independent operations in late 2021, its core regenerative programs and the development of Remelix continue under its parent company, Prudentix.
- Therapeutic areas
- Rheumatology
- Modalities
- Recombinant proteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Planeeria.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Planeeria.